GlassScriptPhysician profile
Brian David Sullivan
NPI 1831551654
$36,868.13
in general payments reported to CMS, 2019-2025
18 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2021: $28K · 2022: $5,120 · 2023: $1,339 · 2024: $379 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107 · Travel and Lodging: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.66 |
| Travel and Lodging | $822.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $22,543.29 | 2021-2023 | Arthrex |
| Cdc Medical LLC | $4,681.00 | 2019-2021 | |
| Medical Device Business Services, INC. | $3,898.04 | 2021 | |
| Medinc of Texas | $3,788.54 | 2021-2022 | |
| Smith+Nephew, INC. | $1,189.22 | 2023-2025 | Real Intelligence, Journey II, Journey |
| Stryker Corporation | $269.68 | 2022-2025 | Blueprint Patient Specific Instrumentation |
| Zimmer Biomet Holdings, INC. | $115.07 | 2024 | Comprehensive Shoulder System |
| Bioventus LLC | $81.92 | 2024-2025 | Durolane, Xcell, Exogen Ultrasound Bone Healing System |
| Linvatec Corporation | $53.14 | 2023 | Biobrace 23mm |
| Catalyst Orthoscience | $51.04 | 2023 | Archer 3d Software, Csr & R1 Reverse Total Shoulder Systems, R1 Reverse Total Shoulder |
| Piedmont Plus Innovation | $49.42 | 2023 | |
| Collegium Pharmaceutical, INC. | $39.63 | 2023-2025 | Belbuca, Xtampza |
| Depuy Synthes Sales INC. | $24.11 | 2025 | Monovisc |
| Averitas Pharma INC. | $22.30 | 2024 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $20.47 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $14.48 | 2025 | Exparel |
| Electronic Waveform Lab, INC. | $13.47 | 2024 | |
| Fidia Pharma USA INC. | $13.31 | 2024 | Hyalgan, Triluron, Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.